Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Q1 2025 Tether Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex and I'll be coordinating the call today. If you'd like to ask a question once the presentation has finished, please press star, followed by one on your telephone keypad. And I'll hand it over to your host, Christopher Stivo, Head of Investor Relations to begin. Please go ahead. Thank you, Alex. Good morning, everyone. In the course of this call, we're going to be making some forward-looking statements, and any statements we make are valid only as of today, and we undertake no obligation to update them in the future. And if you have any additional questions on our forward-looking statements, you can see the relevant sections of our SEC filings under Forms 10-K and 10-Q. Additionally, during today's call, all comments made to revenue growth year over year will be in local currency terms unless otherwise noted by one of us. And with that, I will turn it over to Richard Francis. Thank you, Chris, and good morning and good afternoon, everybody. Thank you for joining the call. Looking forward to talking to you through this agenda today where myself, Eric Khalid, my CFO, and Eric Hughes, the head of R&D. We're going to go through the business update for Q1, but also we're going to give you an insight into the path towards our 2027 targets and the confidence and the high level of confidence we have in achieving those. Now, as you remember, this all started in 2023 with the pivot to growth strategy being launched. And this was to return the company to growth. And as you can now see, this is our ninth consecutive quarter of growth. And this has been driven by executing on our pillars to live on our growth engines, step up innovation, sustain the generic spare hou...